Abstract
Abstract mTOR is an important factor for cell proliferation. It is reported that overexpression of mTOR is associated with poor prognosis in many cancers. We examined mTOR expression in cervical cancer and association with clinico-pathological findings. 34 patients were examined about mTOR expression by immuno-histochemistry. The result was classified into 3 categories, i.e negative, weak positive and strong positive. 25 patients were treated with concurrent chemoradiotherapy, 8 ptients were treated with hysterectomy and one patient was treated with chemotherapy as main treatment. Overexpression of mTOR was recognized in 24(71%) patients. The frequency of parametrial invasion and lymphnode metastasis in mTOR positive and negative were 17/24 (71%) versus 3/10 (30%) (p=0.027) and 14/24 (58%) versus 2/10 (20%) (p=0.041). In 25 cases treated with radiotherapy, mTOR overexpression was seen in 19 cases (76%). Averages of tumor diameter in mTOR positive and negative cases were 4.8 cm and 5.0cm respectively (n.s). In 5 local recurrent cases treated with chemo-radiotherpy, tumor diameters of pre-treatment were 0, 3.5, 5.5, 7 and 7cm. Small tumor was included in local recurrence in mTOR positive cases. It is suggested that mTOR overexpression promotes lymphnode and parametrial metastasis and is associated with radio-resistance. In case of mTOR overexpression, we need to consider treatment by hysterectomy if the tumor is resectable or usage of mTOR inhibitor at chemo-radiation, and control of mTOR expression is important in treatment of cervical cancer. Citation Format: Masato Nishimura, Kanako Yoshida, Hiroyuki Furumoto, Minoru Irahara. mTOR overexpression is associated with radio-resistance and worse prognosis of cervical cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 433. doi:10.1158/1538-7445.AM2013-433
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
